Avid Bioservices Appoints Michael Alston, Jr. as Vice President, Operations
22 September 2022 - 2:05PM
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced the appointment of Michael Alston, Jr.
as vice president, operations. Mr. Alston was promoted from Avid’s
director of project engineering, a role in which he led all of the
company’s ongoing facility expansions. In his new position, he will
continue to oversee these projects including the Myford South
expansion, as well as the construction of Avid’s new dedicated cell
and gene therapy facility.
Mr. Alston has more than 15 years of experience
spanning operational and capital management responsibilities
supporting cGMP manufacturing, facilities, engineering, and
environmental, health and safety (EHS) functions. Prior to joining
Avid in 2019, Mr. Alston was associate director, engineering and
facilities with Sterogene Bioseperations, where he led the
biotechnology company’s engineering, facilities, maintenance,
safety and environmental functions. During this time, he led the
design, construction and launch of Sterogene’s new, more than $5
million cGMP laboratory and pilot plant manufacturing facility. Mr.
Alston has also previously served in senior roles within Merck’s
viral vaccine manufacturing unit, including senior manufacturing
supervisor. His career has included senior engineering, facilities
and operational management positions with Unilever and ConAgra
Foods.
“Michael’s promotion to vice president,
operations, is well deserved based on the exceptional job he has
done leading and overseeing our multiple facility expansion and
buildout projects, which are complex and occurring concurrently.
His extensive background in both engineering and operations is
ideally suited for his new role and the responsibilities that come
with the position. We are thrilled to be able to promote such a
talented individual from within Avid to this key role and look
forward to Michael’s continued contributions to the company’s
success,” said Nick Green, president and chief executive officer of
Avid Bioservices.
About Avid Bioservices,
Inc.
Avid Bioservices (NASDAQ:CDMO), an S&P
SmallCap 600 company, is a dedicated contract development and
manufacturing organization (CDMO) focused on development and CGMP
manufacturing of biologics. The company provides a comprehensive
range of process development, CGMP clinical and commercial
manufacturing services for the biotechnology and biopharmaceutical
industries. With 29 years of experience producing monoclonal
antibodies and recombinant proteins, Avid's services include CGMP
clinical and commercial drug substance manufacturing, bulk
packaging, release and stability testing and regulatory submissions
support. For early-stage programs the company provides a variety of
process development activities, including upstream and downstream
development and optimization, analytical methods development,
testing and characterization. The scope of our services ranges
from standalone process development projects to full development
and manufacturing programs through
commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Okt 2023 bis Okt 2024